Verastem Oncology (VSTM) announced that it has dosed the first patient in a phase I/II study evaluating its KRAS G12D inhibitor, GFH375/VS-7375, for treating KRAS G12D mutant solid tumors. Verastem’s collaboration partner GenFleet Therapeutics is conducting the study in China.Shares of VSTM were up 12.8% on Jul 12 following the announcement of the news.Verastem entered into a collaboration agreement with GenFleet in 2023, wherein GFH375/VS-7375 was selected as its lead program. GFH375/VS-7375 is an oral, po ...